Tag: chi-med

November 29, 2018

Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors

Hutchison China MediTech (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib...
October 18, 2018

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China

Hutchison China MediTech (AIM/Nasdaq:HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in combination...